PTGS2 and breast cancer: Recent findings by Hunter et al. demonstrated that the overexpression of miR-526 and miR-655 in the poorly metastatic MCF7 breast cancer cell line resulted in the significant upregulation of lymphangiogenesis and angiogenesis markers, including VEGF-C, VEGF-A, VEGF-D, COX-2, LYVE-1, VEGFR-1, and VEGFR-2.